- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04975256
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
December 6, 2022 updated by: Mirati Therapeutics Inc.
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors with a KRAS G12C mutation.
MRTX849 is an orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 1
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Next Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
- Unresectable or metastatic disease
- No available treatment with curative intent
- Adequate organ function
Exclusion Criteria:
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
- Other active cancer
- Cardiac abnormalities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation
Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
|
KRAS G12C inhibitor
Other Names:
SOS1 Inhibitor
Other Names:
|
Experimental: Dose expansion
Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
|
KRAS G12C inhibitor
Other Names:
SOS1 Inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize the number of patients with treatment emergent adverse events of the combination regimen in patients with advanced solid tumor malignancies with KRAS G12C mutation
Time Frame: 20 months
|
Number of participants with treatment related adverse events
|
20 months
|
Evaluate Pharmacokinetics of the combination regimen
Time Frame: 20 months
|
Blood plasma concentration
|
20 months
|
Establish Maximum Tolerated Dose
Time Frame: 12 months
|
Number of patients with dose limiting toxicity
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate preliminary clinical activity of the combination regimen
Time Frame: 20 months
|
Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)
|
20 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 12, 2021
Primary Completion (Actual)
November 2, 2022
Study Completion (Actual)
November 15, 2022
Study Registration Dates
First Submitted
July 6, 2021
First Submitted That Met QC Criteria
July 14, 2021
First Posted (Actual)
July 23, 2021
Study Record Updates
Last Update Posted (Estimate)
December 8, 2022
Last Update Submitted That Met QC Criteria
December 6, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Colonic Neoplasms
- Antineoplastic Agents
- Adagrasib
Other Study ID Numbers
- 849-014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Cancer
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Cedars-Sinai Medical CenterRecruitingNeoplasms | Cancer | Cancer, MetastaticUnited States
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
Oslo University HospitalVestre Viken Hospital Trust; University Hospital of North Norway; Ostfold Hospital... and other collaboratorsRecruitingCancer MetastaticNorway
Clinical Trials on MRTX849
-
M.D. Anderson Cancer CenterMirati Therapeutics Inc.RecruitingMetastatic Pancreatic CancerUnited States
-
Zai Lab (Shanghai) Co., Ltd.Mirati Therapeutics Inc.Active, not recruitingAdvanced or Metastatic Solid TumorChina
-
Mirati Therapeutics Inc.Approved for marketingMetastatic Cancer | Advanced Cancer | Malignant NeoplasmUnited States
-
Mirati Therapeutics Inc.RecruitingSolid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal CancerUnited States, Puerto Rico
-
Mirati Therapeutics Inc.NovartisActive, not recruitingMetastatic Cancer | Advanced Cancer | Malignant Neoplastic DiseaseUnited States
-
Mirati Therapeutics Inc.RecruitingMetastatic Cancer | Advanced Cancer | Malignant Neoplasm of LungKorea, Republic of, United States, Turkey, France, Taiwan
-
M.D. Anderson Cancer CenterMirati Therapeutics Inc.RecruitingAdvanced Solid Tumor | Non-small Cell Lung CancersUnited States
-
Mirati Therapeutics Inc.Active, not recruitingAdvanced Solid TumorUnited States
-
Bristol-Myers SquibbActive, not recruitingAdvanced Solid TumorsUnited States, France, Argentina, Australia, Belgium, Israel, Italy, Spain
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States